论文部分内容阅读
2012年12月,美国免疫实施咨询委员会(Advisory Committee on Immunization Practices,ACIP)会议表决通过,推荐6周龄~18月龄感染脑膜炎球菌(Neisseria meningitidis,Nm)高风险的婴幼儿,接种C群和Y群脑膜炎球菌疫苗(Meningococcal Vaccine,MenV)。b型流行性感冒(流感)嗜血杆菌-C群和Y群Nm-破伤风类毒素(破类)结合疫苗[Haemophilus influenzae Type b(Hib)-Groups C and Y Meningococcal-Tetanus Toxoid(TT)Conjugate Vaccine,Hib-MenCY-TT(商品名:MenHibrix,葛兰素史克生物制品公司)]获得批准上市,用来预防Hib、C群和Y群Nm所引起的侵袭性疾病。Hib-MenCY-TT不能预防B群、W135群和A群Nm病,婴幼儿Nm病常见的血清型是B群,4价脑膜炎球菌多糖结合疫苗(4-valent Meningococca Polysaccharide Conjugate Vaccine,MPCV4)含有W135群和A群组分。
In December 2012, a vote was approved by the AC Advisory Committee on Immunization Practices (ACIP), recommending infants and young children aged 6 weeks to 18 months who were at high risk of infection with Neisseria meningitidis (Nm) And Meningococcal Vaccine (MenV). Haemophilus influenzae Type b (Hib) -Groups C and Y Meningococcal-Tetanus Toxoid (TT) Conjugate (influenza) Haemophilus influenzae-C and Y-group Nm-tetanus toxoid Vaccine, Hib-MenCY-TT (trade name: MenHibrix, GSK Biological Products)] was approved for the prevention of invasive disease caused by Hib, C and Y group Nm. Hib-MenCY-TT can not prevent B group, W135 group and A group Nm disease. The common serotype of infant Nm disease is B group, and the 4-valent Meningococcosis Polysaccharide Conjugate Vaccine (MPCV4) contains W135 and Group A components.